BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37782888)

  • 21. A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer.
    Hewitt DB; Nissen N; Hatoum H; Musher B; Seng J; Coveler AL; Al-Rajabi R; Yeo CJ; Leiby B; Banks J; Balducci L; Vaccaro G; LoConte N; George TJ; Brenner W; Elquza E; Vahanian N; Rossi G; Kennedy E; Link C; Lavu H
    Ann Surg; 2022 Jan; 275(1):45-53. PubMed ID: 33630475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A successful case of locally advanced pancreatic cancer undergoing curative distal pancreatectomy with en bloc celiac axis resection after combination chemotherapy of nab-paclitaxel with gemcitabine.
    Hiyoshi M; Nanashima A; Wada T; Tsuchimochi Y; Hamada T; Yano K; Imamura N; Fujii Y
    Clin J Gastroenterol; 2017 Dec; 10(6):551-557. PubMed ID: 29086227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Conversion Surgery for Initially Unresectable Locally Advanced Pancreatic Cancer Following Gemcitabine plus Nab-Paclitaxel - A Case Report].
    Nakamoto S; Nishiyama R; Kaneda T; Yokota M; Kawamata H; Tajima H; Kaizu T; Kumamoto Y; Yamauchi H; Okuwaki K; Iwai T; Imaizumi H; Suzuki E; Hara A; Ichinoe M; Kida M; Watanabe M
    Gan To Kagaku Ryoho; 2017 Feb; 44(2):173-176. PubMed ID: 28223678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
    Wijetunga AR; Chua TC; Nahm CB; Pavlakis N; Clarke S; Chan DL; Diakos C; Maloney S; Ashrafi-Zadeh A; Kneebone A; Hruby G; Jamieson NB; Gill A; Mittal A; Samra JS
    Eur J Surg Oncol; 2021 Oct; 47(10):2543-2550. PubMed ID: 33952409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation.
    Amodeo S; Masi A; Melis M; Ryan T; Hochster HS; Cohen DJ; Chandra A; Pachter HL; Newman E
    J Gastrointest Oncol; 2018 Oct; 9(5):922-935. PubMed ID: 30505595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation.
    Koay EJ; Zaid M; Aliru M; Bagereka P; Van Wieren A; Rodriguez MJ; Jacobson G; Wolff RA; Overman M; Varadhachary G; Pant S; Wang H; Tzeng CW; Ikoma N; Kim M; Lee JE; Katz MH; Tamm E; Bhosale P; Taniguchi CM; Holliday EB; Smith GL; Ludmir EB; Minsky BD; Crane CH; Koong AC; Das P; Wang X; Javle M; Krishnan S
    Int J Radiat Oncol Biol Phys; 2022 Nov; 114(3):444-453. PubMed ID: 35863672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
    Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
    Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
    Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
    BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration.
    Polistina F; Costantin G; Casamassima F; Francescon P; Guglielmi R; Panizzoni G; Febbraro A; Ambrosino G
    Ann Surg Oncol; 2010 Aug; 17(8):2092-101. PubMed ID: 20224860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
    Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM
    BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy: a new method of neoadjuvant chemotherapy for stage III unresectable non-small cell lung cancer.
    Lu B; Sun L; Yan X; Ai Z; Xu J
    Med Oncol; 2015 Jan; 32(1):345. PubMed ID: 25429832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving antitumor outcomes for palliative intratumoral injection therapy through lecithin- chitosan nanoparticles loading paclitaxel- cholesterol complex.
    Chu XY; Huang W; Wang YL; Meng LW; Chen LQ; Jin MJ; Chen L; Gao CH; Ge C; Gao ZG; Gao CS
    Int J Nanomedicine; 2019; 14():689-705. PubMed ID: 30774330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete pathological remission of locally advanced, unresectable pancreatic cancer (LAPC) after intensified neoadjuvant chemotherapy.
    Hartlapp I; Müller J; Kenn W; Steger U; Isbert C; Scheurlen M; Germer CT; Einsele H; Kunzmann V
    Onkologie; 2013; 36(3):123-5. PubMed ID: 23486001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EUS-guided paclitaxel injection as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation before surgery for localized or locoregional esophageal cancer: a multicenter prospective randomized trial.
    DeWitt JM; Murthy SK; Ardhanari R; DuVall GA; Wallner G; Litka P; Daugherty C; Fowers K
    Gastrointest Endosc; 2017 Jul; 86(1):140-149. PubMed ID: 27890801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer.
    Yamada S; Fujii T; Yokoyama Y; Kawashima H; Maeda O; Suzuki K; Okada T; Ono E; Yamaguchi J; Takano N; Takami H; Hayashi M; Niwa Y; Hirooka Y; Ito Y; Naganawa S; Ando Y; Nagino M; Goto H; Kodera Y
    Cancer Chemother Pharmacol; 2018 May; 81(5):815-821. PubMed ID: 29502139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.
    Schad F; Atxner J; Buchwald D; Happe A; Popp S; Kröz M; Matthes H
    Integr Cancer Ther; 2014 Jul; 13(4):332-40. PubMed ID: 24363283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Locally advanced pancreatic cancer successfully treated by distal pancreatectomy with celiac axis resection (DP-CAR) after S-1 with radiation therapy followed by gemcitabine/nab-paclitaxel therapy: a case report.
    Ariake K; Motoi F; Mizuma M; Murakami K; Takadate T; Ohtsuka H; Fukase K; Masuda K; Hayashi H; Nakagawa K; Sakata N; Morikawa T; Maeda S; Naitoh T; Egawa S; Unno M
    Surg Case Rep; 2017 Dec; 3(1):15. PubMed ID: 28101795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.
    Botta GP; Huynh TR; Spierling-Bagsic SR; Agelidis A; Schaffer R; Lin R; Sigal D
    Cancer Med; 2023 Apr; 12(7):7713-7723. PubMed ID: 36478411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study.
    Weniger M; Moir J; Damm M; Maggino L; Kordes M; Rosendahl J; Ceyhan GO; Schorn S;
    Surg Oncol; 2020 Dec; 35():285-297. PubMed ID: 32949968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
    Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
    Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.